[3H]CGP12177   Click here for help

GtoPdb Ligand ID: 5387

Synonyms: [3H]-CGP12177 | [3H]CGP 12177
 Ligand is labelled  Ligand is radioactive
Compound class: Synthetic organic
Comment: Pharmacological characterization of CGP12177 as a partial agonist at the human β2-adrenoceptor was reported in [5].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 3
Hydrogen bond donors 4
Rotatable bonds 6
Topological polar surface area 90.14
Molecular weight 279.16
XLogP 0.62
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES OC(COc1cccc2c1[nH]c(=O)[nH]2)CNC(C)(C)C
Isomeric SMILES OC(COc1cccc2c1[nH]c(=O)[nH]2)CNC(C)(C)C
InChI InChI=1S/C14H21N3O3/c1-14(2,3)15-7-9(18)8-20-11-6-4-5-10-12(11)17-13(19)16-10/h4-6,9,15,18H,7-8H2,1-3H3,(H2,16,17,19)
InChI Key UMQUQWCJKFOUGV-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

References
1. Baker JG. (2005)
The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
Br J Pharmacol, 144 (3): 317-22. [PMID:15655528]
2. Baker JG. (2010)
A full pharmacological analysis of the three turkey β-adrenoceptors and comparison with the human β-adrenoceptors.
PLoS ONE, 5 (11): e15487. [PMID:21152092]
3. Baker JG. (2026)
Comparing the Molecular Pharmacological Properties of Existing β-Blockers to Determine the Theoretically Most "Ideal" Anti-Cancer β-Blocker.
Pharmacol Res Perspect, 14 (1): e70214. [PMID:41485077]
4. Baker JG, Gardiner SM, Woolard J, Fromont C, Jadhav GP, Mistry SN, Thompson KSJ, Kellam B, Hill SJ, Fischer PM. (2017)
Novel selective β1-adrenoceptor antagonists for concomitant cardiovascular and respiratory disease.
FASEB J, 31 (7): 3150-3166. [PMID:28400472]
5. Baker JG, Hall IP, Hill SJ. (2002)
Pharmacological characterization of CGP 12177 at the human beta(2)-adrenoceptor.
Br J Pharmacol, 137 (3): 400-8. [PMID:12237261]
6. Baker JG, Proudman RG, Hawley NC, Fischer PM, Hill SJ. (2008)
Role of key transmembrane residues in agonist and antagonist actions at the two conformations of the human beta1-adrenoceptor.
Mol Pharmacol, 74 (5): 1246-60. [PMID:18687809]
7. Baker JG, Proudman RG, Hill SJ. (2013)
Impact of polymorphic variants on the molecular pharmacology of the two-agonist conformations of the human β1-adrenoceptor.
PLoS One, 8 (11): e77582. [PMID:24250787]
8. Baker JG, Proudman RG, Hill SJ. (2015)
Salmeterol's extreme β2 selectivity is due to residues in both extracellular loops and transmembrane domains.
Mol Pharmacol, 87 (1): 103-20. [PMID:25324048]
9. Soave M, Cseke G, Hutchings CJ, Brown AJH, Woolard J, Hill SJ. (2018)
A monoclonal antibody raised against a thermo-stabilised β1-adrenoceptor interacts with extracellular loop 2 and acts as a negative allosteric modulator of a sub-set of β1-adrenoceptors expressed in stable cell lines.
Biochem Pharmacol, 147: 38-54. [PMID:29102678]
10. Warne T, Moukhametzianov R, Baker JG, Nehmé R, Edwards PC, Leslie AG, Schertler GF, Tate CG. (2011)
The structural basis for agonist and partial agonist action on a β(1)-adrenergic receptor.
Nature, 469 (7329): 241-4. [PMID:21228877]